Global Cancer Coalition Seeks To Increase Access To Medicines In LLMICs

Members Include Medicines Patent Pool, Teva And Generics Industry Body IGBA

The Union for International Cancer Control has established the Access to Oncology Medicines Coalition to facilitate access to cancer drugs in low and lower-middle-income countries.

Arm of a patient receiving chemotherapy
ATOM will support the implementation of “intensive coordinated capacity building activities” in up to 10 countries. • Source: Shutterstock

The Union for International Cancer Control and its partners, including the Medicines Patent Pool and International Generic and Biosimilar medicines Association as well as firms such as Teva, have announced the establishment of the Access to Oncology Medicines Coalition, a global partnership designed to facilitate access to essential cancer medicines in low- and lower-middle-income countries. The ATOM Coalition said it also aims to help these countries “develop the capacity for their proper use.”

MPP executive director Charles Gore said: “For us at MPP, it is so important that people everywhere have access to...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Archive

ADHD Medications and Cardiovascular Effects: New Data Revealed. (A Comprehensive Evaluation of Emerging Clinical and Epidemiological Evidence on the Cardiovascular Effects Associated with Prescribed Medications for Attention Deficit Hyperactivity Disorder) - Clone - Clone

 
• By 

A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.

Testing-Rising

 
• By 

Testing-Rising xxxx

bhvyuguig

lnkbkb

test 1

test 1

More from Generics Bulletin

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C10

 
• By 

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C9

 
• By 

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C8

 
• By 

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.